Patients with certain types of genetically confirmed congenital myasthenic syndromes (CMS) can help Catalyst evaluate the safety and effectiveness of amifampridine phosphate for the treatment of this condition. If you are unsure of your CMS diagnosis, genetic testing will be provided to confirm CMS.
Other clinical testing with this medication has already occurred; however, specific studies for its use in CMS is needed to gain FDA approval.
For more information on study of amifampridine phosphate for the treatment of CMS, please see the following link: clinicaltrials.gov/ct2/show/NCT02562066
